We compared the serologic responses of 1 dose versus 2 doses of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A 2-dose boosting regimen with a variant vaccine did not increase the magnitude or the durability of the serological responses compared to a single variant vaccine boost.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11032204 | PMC |
| http://dx.doi.org/10.1093/infdis/jiad323 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.
Nat Commun
December 2024
Laboratory of Aging Research and Cancer Drug Target, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
The immune escape capacities of XBB variants necessitate the authorization of vaccines with these antigens. In this study, we produce three recombinant trimeric proteins from the RBD sequences of Delta, BA.5, and XBB.
View Article and Find Full Text PDFEvaluation of protective immunity in chickens vaccinated with combined IB H120/D274 and IB H120 against IS/1494/06 in Iran.
Arch Razi Inst
June 2024
Department of Clinical Science, Faculty of Veterinary Medicine, Karaj Branch, Islamic Azad University, Alborz, Iran.
Infectious bronchitis virus (IBV) has a variety of serotypes that cause many problems in the poultry industry. Two H120 and H120-D274 live vaccines were evaluated against strain IS/1494/06 (variant 2) IBV challenge. The study aimed to determine whether it was possible to achieve success in controlling disease symptoms and pathological lesions and reducing virus shedding by combining two types of vaccines against different severities of poultry IBV.
View Article and Find Full Text PDFClinical advancements in mRNA vaccines against viral infections.
Clin Immunol
December 2024
Department of Microbiology, Gachon University College of Medicine, Incheon, Republic of Korea; Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea; Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Republic of Korea; Korea mRNA Vaccine Initiative, Gachon University, Seongnam, Republic of Korea. Electronic address:
Over the last decade, mRNA vaccines development has shown significant advancement, particularly during the COVID-19 pandemic. This comprehensive review examines the efficacy of pivotal vaccines against emerging COVID-19 variants and strategies for enhancing vaccine effectiveness. It also explores the versatility of mRNA technology in addressing other infectious diseases such as influenza, respiratory syncytial virus, HIV, cytomegalovirus, Ebola, Zika, Rabies, and Nipah viruses.
View Article and Find Full Text PDFPossible scenarios for the spread of mpox outside the endemic focus in Africa.
Int J Infect Dis
December 2024
PandemiX Center, Dept of Science & Environment, Roskilde University, Roskilde, Denmark. Electronic address:
The recent expansion of mpox in Africa is characterized by a dramatic increase in zoonotic transmission (clade Ia) and the emergence of a new clade Ib that is transmitted from human-to-human (H2H) by close contact. Clade Ia does not pose a threat in areas without zoonotic reservoir. But clade Ib may spread widely, as did the clade IIb that since 2022 has spread globally among MSM.
View Article and Find Full Text PDFControlling vaccine kinetics using tannic acid for enhanced humoral immunity.
J Control Release
December 2024
John A Paulson School of Engineering & Applied Sciences, Allston, MA 02134, USA; Wyss Institute of Biologically Inspired Engineering, Boston, MA 02215, USA. Electronic address:
Despite the success of global vaccination campaigns, vaccine access in low-resource settings is an ongoing challenge. Subunit vaccines are a well-established and clinically scalable intervention, yet they have achieved limited success for poorly immunogenic antigens such as those associated with SARS-CoV-2. Delivery strategies that promote gradual release of subunit vaccines from the injection site offer the potential to improve humoral immunity by enhancing lymph node exposure, however, clinical implementation of this strategy is challenging due to poor scalability and high costs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!